The Lynx Group
Cholangiocarcinoma News

Monthly Minutes

Web Exclusives — December 20, 2021
Infigratinib demonstrates significant efficacy and a manageable safety profile in patients with previously treated, locally advanced or metastatic CCA with an FGFR2 gene fusion or rearrangement.
Read More

Web Exclusives — December 20, 2021
The ClarIDHy trial demonstrated safety and efficacy of ivosidenib in patients with previously treated metastatic CCA harboring an IDH1 mutation.
Read More

Web Exclusives — December 20, 2021
Initial results of the phase 2 FOENIX-CCA2 study demonstrated that futibatinib demonstrated efficacy and a manageable safety profile in patients with previously treated iCCA harboring an FGFR2 fusion or rearrangement.
Read More

Web Exclusives — December 20, 2021
The phase 2 FIDES-01 study demonstrated that derazantinib resulted in objective responses and a manageable safety profile in patients with previously treated iCCA with an FGFR2 fusion or rearrangement.
Read More

Web Exclusives — December 20, 2021
Results from a phase 1 study showed that the bispecific HER2-targeted antibody zanidatamab is well-tolerated and demonstrates clinical activity in patients with HER2-overexpressing biliary tract cancer.
Read More

Web Exclusives — December 20, 2021
The NIFE study demonstrated the efficacy and safety of the nal-IRI-plus-5-FU/LV regimen as first-line therapy in patients with advanced biliary tract cancer, with a clear benefit over gemcitabine/cisplatin in extrahepatic cholangiocarcinoma.
Read More


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: